ARX517
Phase 1/2- Indications
- Metastatic castration-resistant prostate cancer
Company intelligence / Profile preview
Ambrx
La Jolla, California, United Statesambrx.com ↗
- Ownership
- Public · AMAM
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
Ambrx has demonstrated promising early clinical results with its lead ADCs. ARX517 showed preliminary safety and efficacy in advanced prostate cancer patients at ESMO2023. ARX788 has advanced through Phase I trials for HER2-positive cancers. The company’s technology enables highly stable, site-specific ADCs designed to improve therapeutic index over conventional approaches.[1]
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Bispecific antibodiesModified cytokinesProtein therapeutics[1][3][6]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Multiple collaborations with major pharmaceutical companies on drug candidates generated using Ambrx technology; specific partners not named in the provided sources but historically included large pharma and Chinese investors.[4]
04
Financials
- Market cap
- $1.8B
- Total revenue
- $53K
- Enterprise value
- $1.6B
Beyond the preview
Go deeper on Ambrx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambrx.